Sugi Predict

Sugi Predict / Compounds / SCHEMBL4854592

SCHEMBL4854592

SCHEMBL4854592

COc1ccccc1C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.64

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.64
▸ KMT2A Q03164 5/20 0.64
▸ ALDH1A1 P00352 3/20 0.55
▸ LMNA P02545 1/20 0.55
▸ GPR119 Q8TDV5 1/20 0.54
▸ TP53 P04637 1/20 0.53
▸ PDE4B Q07343 1/20 0.52
▸ DRD2 P14416 1/20 0.51
▸ MAPT P10636 2/20 0.51
▸ NAMPT P43490 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ CHRM4 P08173 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25044033 0.92 MEN1 (0.59) MEN1KMT2AALDH1A1LMNAGPR119
SCHEMBL5104610 0.87 PDE4B (0.53) MEN1KMT2AGPR119PDE4BMAPT
SCHEMBL25044121 0.86 MEN1 (0.51) MEN1KMT2APDE4BNAMPT
SCHEMBL8534478 0.86 MEN1 (0.71) MEN1KMT2AALDH1A1DRD2MAPT
SCHEMBL6922546 0.86 GPR119 (0.51) MEN1KMT2AALDH1A1LMNAGPR119
SCHEMBL12712674 0.86 CHRM4 (0.54) MEN1KMT2AALDH1A1GPR119MAPT
SCHEMBL29691266 0.86 GPR119 (0.51) MEN1KMT2AALDH1A1LMNAGPR119
SCHEMBL23209949 0.86 GPR119 (0.51) MEN1KMT2AALDH1A1LMNAGPR119
SCHEMBL23228679 0.85 GPR119 (0.50) MEN1KMT2AALDH1A1LMNAGPR119
SCHEMBL4853312 0.85 ALDH1A1 (0.54) MEN1KMT2AALDH1A1LMNAGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025021120-A1 5-HT2A RECEPTOR AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2025-01-30 — — WO disclosed
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-07-06 — — US disclosed
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2023-07-06 — — US disclosed
US-11548865-B2 2-azaspiro[3.4]octane derivatives as M4 agonists NOVARTIS AG (CH) 2023-01-10 — — US disclosed
US-11261164-B2 Small molecule agonists of neurotensin receptor 1 Sanford Burnham Prebys Medical Discovery Institute (US) 2022-03-01 — — US disclosed
EP-2938608-B1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 SANFORD BURNHAM MED RES INST (US) 2021-08-04 — — EP disclosed
WO-2021070090-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS AG (CH) 2021-04-15 — — WO disclosed
US-20210107889-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2021-04-15 — — US disclosed
EP-3083588-B1 AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO LTD (CN) 2020-12-09 — — EP disclosed
US-20200354324-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE 2020-11-12 — — US disclosed
US-7375227-B2 Quinoline derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-05-20 — — US disclosed
US-7375227-B2 Quinoline derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-05-20 — — US disclosed
US-7375227-B2 Quinoline derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2008-05-20 — — US disclosed
EP-1499607-B1 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2005-12-07 — — EP disclosed
EP-0937715-B1 TETRAHYDROBENZINDOLE COMPOUNDS MEIJI SEIKA KAISHA (JP) 2005-06-01 — — EP disclosed
US-20050043535-A1 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2005-02-24 — — US disclosed
EP-1499607-A1 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS Actelion Pharmaceuticals Ltd. (CH) 2005-01-26 — — EP disclosed
WO-2003048154-A1 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO) -QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2003-06-12 — — WO disclosed
US-6355642-B1 PSYCHOLOGICAL DISORDERS AND BRAIN DISORDERS MEIJI SEIKA KAISHA, LTD. (JP) 2002-03-12 — — US disclosed
EP-0937715-A1 TETRAHYDROBENZINDOLE COMPOUNDS MEIJI SEIKA KAISHA LTD. (JP) 1999-08-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11261164-B2 Small molecule agonists of neurotensin receptor 1 NTSR1, NTSR2, VIPR1 MEN1 921/4885KMT2A 4362/4885ALDH1A1 3294/4885
US-20210107889-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 MEN1 1411/4885KMT2A 1568/4885ALDH1A1 1359/4885
US-20050043535-A1 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists UTS2R, NTSR2, PLAUR MEN1 2285/4885KMT2A 2523/4885ALDH1A1 2993/4885
US-20230212139-A1 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS CHRM2, CHRM1, CHRM3 MEN1 1411/4885KMT2A 1568/4885ALDH1A1 1359/4885
US-20200354324-A1 SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 NTSR1, NTSR2, VIPR1 MEN1 921/4885KMT2A 4362/4885ALDH1A1 3294/4885
US-11548865-B2 2-azaspiro[3.4]octane derivatives as M4 agonists CHRM2, CHRM1, CHRM3 MEN1 1411/4885KMT2A 1568/4885ALDH1A1 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.